You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.

Clinical Advances in

Inflammatory Bowel Disease: The Evolving Role of Biologics

New biologics with a novel mechanism of action offer new options for patients with inflammatory bowel disease (IBD) not optimally controlled with anti-tumor necrosis factor (TNF) agents. Integration of biologics into clinical practice together with emerging strategies for management of IBD -- including early intervention, new treatment goals, and personalized care -- will allow physicians to improve patient outcomes and potentially alter the progressive course of IBD.

Supported by an independent educational grant from


CME Activities

Polling Question

Related Resources

Downloadable Slide Kits

Advances in Management Strategies for Ulcerative Colitis


New Therapeutic Options and Management Strategies in IBD: The Role of Biologics

Educational slides on new biologic agents and treatment strategies in IBD


Inflammatory Bowel Disease: The Unmet Needs and the Expanding Therapeutic Armamentarium


Steering Committee

Peter Irving, MA, MD, FRCP

Steering Committee Chair

Guy's and St Thomas' Hospital
London, United Kingdom

Silvio Danese, MD, PhD

Humanitas University
Rozzano, Italy

Ailsa Hart, MD, FRCP, PhD

Professor of Practice
St. Mark's Hospital
Department of Surgery and Cancer
Imperial College
London, UK

Geert D'Haens, MD, PhD, AGAF

Academic Medical Center
Amsterdam, The Netherlands

Gerhard Rogler, MD, PhD

Professor of Medicine
Department of Gastroenterology and Hepatology
University Hospital of Zürich
University of Zürich
Zurich, Switzerland

Stephan Schreiber, MD

Professor of Medicine
Department of Internal Medicine I
Kiel University
Kiel, Germany